The Biden administration wants to expand coverage of anti-obesity medications to millions on Medicare, Medicaid.

Whether this proposed rule actually has any impact remains to be seen, especially with a new administration led by Donald ...

About 42% of U.S. adults are obese, the CDC says. GLP-1 medications have changed the picture for people hoping to reduce ...

People who talk in their sleep may be at greater risk of stroke, according to a study of 8,001 Chinese adults. The risk was ...

Semaglutide and liraglutide are associated with a reduced risk for hospitalization due to alcohol use disorder (AUD).

GLP-1RA dispensing has increased from 2022 and 2023, whereas metabolic bariatric surgery has decreased among individuals with obesity.

When Ozempic and Wegovy don’t work, genetic differences, medical conditions, or side effects could be to blame. Is it normal, ...

Those on the medications, known as GLP-1s or glucagon-like peptide-1, will additionally weigh in four times a month on "smart ...

Compared with standard AUD medications, the use of semaglutide and liraglutide was linked to a lower risk for alcohol use ...

The glucose-lowering and weight-reducing drug class appears to benefit the heart and kidneys in people with lupus and lupus nephritis, independently of glucose-lowering and weight loss.

Interoception research reveals how gut-brain communication via neural, hormonal, and microbial pathways regulates metabolism, ...

The combined reduction in the risk of kidney failure, worsening kidney function and death due to kidney disease was 19, researchers found.